Related Experiment Video
Updated: Mar 25, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Patterns of international normalized ratio values among new warfarin patients with nonvalvular atrial fibrillation
Winnie W Nelson1, Dejan Milentijevic, Li Wang
1aHealth Economics and Outcomes Research (HECOR) Department, Janssen Scientific Affairs, LLC, Raritan, New Jersey bSTATinMED Research, Plano, Texas cSTATinMED Research and Columbia University, New York, USA dMEF University, Istanbul, Turkey eMedical Affairs Biostatistics, Janssen Research and Development, LLC, Raritan, New Jersey, USA.
Insights
Achieving stable international normalized ratio (INR) control significantly reduces warfarin discontinuation in nonvalvular atrial fibrillation (NVAF) patients. INR stabilization is a stronger predictor of continued warfarin use than simply maintaining a therapeutic range.
Area of Science:
- Cardiology
- Pharmacology
- Health Services Research
Background:
- Warfarin is a common anticoagulant for nonvalvular atrial fibrillation (NVAF).
- International Normalized Ratio (INR) control is crucial for warfarin efficacy and safety.
- Limited data exists on the link between INR stability and warfarin discontinuation in NVAF.
Purpose of the Study:
- To evaluate the association between INR stabilization and warfarin discontinuation in NVAF patients.
- To assess INR patterns before and after achieving stabilization.
- To identify predictors of warfarin discontinuation.
Main Methods:
- Retrospective cohort study using Veterans Health Administration data (2007-2012).
- Included NVAF patients (≥18 years) newly initiating warfarin.
- INR stabilization defined as ≥3 consecutive in-range therapeutic INR measurements ≥7 days apart.
- Time in therapeutic range (TTR) calculated using the Rosendaal method.
Main Results:
- 49.4% of 34,346 NVAF patients achieved INR stabilization (mean 98 days).
- Warfarin discontinuation was 4.2 times more likely in patients without INR stabilization (P<0.00001).
- Poor INR control (TTR <60%) increased warfarin discontinuation likelihood by 1.76 times within 1 year (P<0.0001).
Conclusions:
- INR stabilization is a more significant predictor of continued warfarin therapy than poor INR control.
- Effective strategies are needed to maintain therapeutic anticoagulation and reduce warfarin discontinuation in NVAF.
- The findings highlight the importance of achieving and maintaining INR stability for long-term warfarin management.
Abstract:
Limited information exists regarding the relationship between international normalized ratio (INR) control/stability and the discontinuation of warfarin therapy among patients with nonvalvular atrial fibrillation (NVAF). This study evaluated the association between INR stabilization and warfarin discontinuation and assessed INR patterns before and after INR stabilization among patients (≥18 years) with NVAF who newly initiated warfarin (Veterans Health Administration datasets; October 1, 2007 through September 30, 2012). Achievement of INR stabilization (≥3 consecutive in-range therapeutic INR measurements ≥7 days apart) was examined from warfarin initiation through the end of warfarin exposure. Proportion of time in therapeutic range during warfarin exposure was calculated (Rosendaal method) and categorized as at least 60% or less than 60%. Among 34 346 patients, 49.4% achieved INR stabilization (mean time to stabilization, 98 days). Approximately 40% of INR values were out-of-range, even after achieving stabilization. During 30 days following an INR 4.0 or higher, patients had more INR testing than the overall mean (2.51 vs. 1.67 tests). Warfarin discontinuation was 4.2 times more likely among patients without INR stabilization versus those with INR stabilization (P < 0.00001). Patients with poor INR control (time in therapeutic range <60%) were 1.76 times more likely to discontinue warfarin within 1 year (P < 0.0001). INR stabilization is a better predictor of warfarin discontinuation than poor INR control. Improved approaches are necessary to maintain appropriate anticoagulation levels among patients with NVAF.
More Related Videos
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
08:10Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Dysrhythmias III: Characteristics of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Venous Thrombosis IV: Nursing Management